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Abstract Weight loss affects cardiovascular risk profiles in
obese patients. Surgery is not a plausible or viable response to
the public health problem of obesity, given that more than
30% of adults are obese in some countries. However, most
studies investigating the effects of weight loss on the
cardiovascular risk profile are focussed on weight loss and
limited to short-term effects. Since newer data show a rebound
of cardiovascular risks in studies that complete a short-term
follow-up, the question arises whether, and to what extent,
long-term treatments offer a more sustained cardiovascular
benefit beside the extensive or less marked weight loss. Aims
The purpose of this article is to critically review existing data
on the long-term cardiovascular effects of weight loss in
obese and overweight patients treated with dietary interven-
tions, physical activity programmes, behavioural therapy and
pharmacological treatments and their combination. Method
Inclusion criteria were peer-reviewed, randomized controlled
trials (RCT) in the English language which presented data on
cardiovascular effects at a follow-up of at least 18 months
during or after weight reduction interventions. The search
was limited to adults and the publication years between 1990
and 2007. Studies of patients with diagnoses such as
coronary heart disease and cancer, and medically treated
diabetes and hypertension were excluded. Results Twenty-
three studies measured cardiovascular risk factors after
18 months or more. Mean BMI was 33.9 kg/m2 including
13,733 patients. Mean duration of the studies was 37 months
with a dropout rate of 16.1% on average. Regardless of the
absolute amount of weight loss a positive effect on
cardiovascular risk factors such as blood pressure, lipids
and glucose tolerance was found.
Keywords Cardiovascular risk profile .Weight loss .
Non-surgical therapy . RCTs
Abbreviations
BMI body mass index
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LDL cholesterol low-density lipoprotein cholesterol
HDL cholesterol high-density lipoprotein cholesterol
Introduction
Obesity is a problem with an increasing prevalence in the
last several decades. Evidence links obesity to an increased
morbidity and mortality risk and a general limitation in
quality of life in adults (Orzano and Scott 2004). Life
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expectancy is reduced in obese men by 3.3 years and by
6.9 years in obese women compared with normal weight
subjects (Pardo Silva et al. 2006). An increased incidence
of diabetes mellitus, an increased mortality rate (Yan et al.
2006), and an increase in cardiovascular risk factors
(Kannel et al. 2002) are well known. However, obesity may
compromise health status at all levels of risk and greatly
influences physical functioning through inflammatory, endo-
crine and cardiovascular pathways (Lee and Aronne 2007).
Moreover, epidemiologic studies have established that
cardiovascular risk factors are even identifiable in obese
children, predicting a higher cardiovascular risk at adulthood
(Berenson and Srinivasan 2001).
A variety of treatment options is available for helping
people lose weight, including dietary interventions, physical
activity programmes, behavioural therapy and pharmacolog-
ical treatments and their combination. Surgical interventions
are usually a last attempt to support weight change and are
often indicated in only a limited number of patients. Since no
one would seriously consider surgery as a response to the
public health problem of obesity, given that more than 30% of
adults are obese in some countries, we have to emphasise the
long-term cardiovascular effects of weight loss by other
means. For several reasons, surgery especially has been
regarded as the most important tool to reduce cardiovascular
risk in obese or morbidly obese patients. However, most
studies have only investigated short-term effects or have not
been designed in a randomised controlled manner. Since
newer data are showing a rebound of cardiovascular risks in
successfully surgically treated obese patients after 4 to 6 years,
the question arises whether and to what extent long-term
treatments including surgical or non-surgical options offer a
more sustained cardiovascular benefit beside the extensive or
less marked weight loss.
In addition to effects on quality of life and general well-
being, an important objective of obesity interventions is to
reduce cardiovascular risk factors. Non-surgical therapies
have been shown to be effective in changing weight, but
studies have often been restricted to short-term results. Excess
body weight over many years may include irreversible
metabolic effects, since data support a vicious circle of
endocrine, autonomic and central nervous effects of excess
body weight described as the “metabolic domino effect” (Itoh
2003). An overview of the effects of obesity interventions on
long-term cardiovascular risk is therefore warranted.
Methods
We conducted a systematic search and reviewed the
relevant literature on weight loss and its cardiovascular
effects using Medline, Pubmed, EMBASE, Science Cita-
tion Index, PsychInfo and Cochrane Library databases.
Inclusion criteria were (1) peer-reviewed articles in English
language which presented data on cardiovascular effects at
a (2) follow-up of at least 18 months during or after weight
reduction interventions. Search strategies used the key
words obesity, weight loss, weight reduction, and cardio-
vascular risk. The search was limited to (3) adults,
investigated by means of (4) randomised controlled trials
(RCTs), and (5) published between 1990 and 2007. Articles
on patients with additional diagnoses such as coronary heart
disease, cancer, medically treated diabetes and medically
treated hypertension were excluded. In addition to the
database searches, we reviewed references from existing
reviews and meta-analyses. Published papers were then
thoroughly analysed to gather their effects comparing
control to treatment groups.
Results
Summary of studies
Twenty-three RCTs fulfilled the search and inclusion criteria
of long-term changes in cardiovascular risk factors of
18months or more. Studies of dieting, exercising, behavioural
and pharmacological treatment as well as their combinations
were included. Mean follow-up was 34.3±14.6 months. The
parameters investigated were blood pressure, glucose and
insulin, and lipids such as total cholesterol, low-density
lipoprotein (LDL) cholesterol and high-density lipoprotein
(HDL) cholesterol and triglycerides. Participants were either
overweight or obese (mean BMI 33.2±3.77). The studies
included in this review are summarised in Table 1 according
to their intervention style.
Dietary counselling
Dietary modification is one of the major methods of
controlling obesity, but there are a great variety of dietary
intervention methods. Studies examining cardiovascular
long-term effects have shown positive effects on several
cardiovascular risk factors when weight was reduced even
in small amounts.
The Hypertension Prevention Trial Research Group
(1990) was conducted with a total sample of 841 healthy
subjects with a diastolic blood pressure of 78 to 89 mmHg.
They were randomized to one of four dietary counselling
treatment groups (reduced calories, reduced sodium, re-
duced sodium and calories, or reduced sodium and
increased potassium) or a control group. At 3 years, the
low calorie group showed the largest net reduction in mean
blood pressure. Similarly, positive findings on fasting
plasma glucose were shown in a low-fat diet study on
participants with glucose intolerance at 5-year follow-up
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(Swinburn et al. 2001). A recent comparison of a low-fat
diet and a low-glycaemic load diet showed an improvement
in HDL cholesterol and triglycerides in the low-glycaemic
load diet, whereas LDL cholesterol changed in the low-fat
diet (Ebbeling et al. 2007).
Two studies investigated obese and overweight subjects
using proprietary or commercial diet treatments. Heska et al.
(2003) found a better weight loss in a commercial weight
reduction programme (Weight Watchers) than in a self-help
programme and demonstrated significant differences between
the intervention and the control group in plasma insulin level
after the 2nd year. Both groups showed improvements in
lipids, but fasting glucose increased in both groups. These
cardiovascular changes were related to the amount of weight
loss. Similar findings have been described by Ditschuneit
et al. (1999) in a comparison of energy-restricted diet and an
isoenergetic diet with meal replacement by using energy-
controlled food. Those in the isoenergetic diet group lost more
weight in the first months, but both groups showed significant
reductions in systolic blood pressure, triglycerides, glucose
and insulin at the 27-month follow-up. A comparison of a
“prudent diet” (50-60% carbohydrates, 15–20% proteins,
<30% total fat) and Mediterranean-style diet in an overweight
group of patients withmetabolic syndrome showed significant
improvements in pro-inflammatory factors at 2-year follow-
up (Esposito et al. 2004). No other comparable study was
found with obese patients. However, similar findings have
been described in several studies in patients with cardiovas-
cular diseases (Serra-Majem et al. 2006).
Exercise interventions and combinations of exercise
and dietary counselling
The lack of regular exercise activity is thought to add
significantly to the burden of obesity. The recent Cochrane
review of exercise and dietary interventions in obesity
(Shaw et al. 2007a,b) revealed that weight loss was small in
studies of exercise alone, but that the combination of
exercise and dietary change seemed to show better results.
The long-term effects of a 12-week weight reduction
treatment followed by a maintenance programme confirmed
this. Fogelholm et al. (2000) found greater weight mainte-
nance in the exercise group, but most cardiovascular risk
factors, such as systolic blood pressure and fasting glucose,
worsened, althoughHDL cholesterol increased positively, and
the number of cases with a metabolic syndrome decreased in
the exercise group. In a 2-year follow-up of a combined
exercise and diet programme, patients in the intervention
group lost significantly more weight (mean changes −2.4±
0.7 kg) than the controls (−0.1±0.5), who received general
information about dieting, physical activity and weight loss
(Mensink et al. 2003). Additionally, 2-h glucose concentra-
tion following a glucose challenge test declined from 8.7 to
8.0 mmol in the intervention group, but increased in the
control group. Wing et al. (1998) compared a combination
therapy including diet, exercise and behavioural counselling
with a self-help programme (LEARN) over 48 months.
Weight loss was only significant in the intervention group,
but fasting glucose increased in both groups.
The modest weight loss of 4.5 kg reduced the risk for
diabetes by 30%. Lindholm et al. (1995) investigated
apparently healthy volunteers with at least two cardiovascu-
lar risk factors, randomising them to a group-based therapy
combining dietary, physical activity and relaxation interven-
tions with control. Total cholesterol and Framingham risk
scores decreased in the intervention group after 18 months.
Additionally, most of the other cardiovascular risk factors
improved.
Pan et al. (1997) described cumulative incidence
numbers of diabetes after different non-surgical treatments.
Participants were randomly assigned to one diet, exercise,
or diet plus exercise, and a control group. As an effect at
6-year follow-up, diabetes incidence was 67.7% in controls
compared to 43.8% in diet, 41.1% in exercise, and 46% in
the diet plus exercise group.
Psychological interventions
Effects of different psychotherapy styles in obesity and
overweight have been compared and analysed by the
Cochrane Collaboration (Shaw et al. 2007a,b). The majority
of included studies assessed behavioural and cognitive-
behavioural weight reduction strategies and favoured the
combined treatment of behaviour therapy, dietary change and
exercising to improve weight loss. The Cochrane review did
not include any publications with cardiovascular long-term
results. However we identified two studies presenting results
of cardiovascular changes at the 18-month follow-up. Stevens
et al. (2001) examined overweight patients enrolled in a
12-week behavioural therapy programme and reported that
those with weight loss showed a decrease in blood pressure at
18-month follow-up. Additionally, the risk ratio for hyperten-
sion in the intervention group was 0.58 at 18 months and 0.81
at 36 months, and those who lost and maintained at least
4.5 kg weight loss at 6 months had the best improvements in
blood pressure and lowered relative risk for hypertension.
In contrast, no similar effect was found in a 5-year follow-
up of a group of healthy pre-menopausal women (mean BMI
25) after a 20-week intervention, which included cognitive
behavioral therapy, either at the 30-month follow-up or at the
42- or 54-month time points (Kuller et al. 2001). However,
the cognitive behavioural therapy had a significant effect on
lowering low-density cholesterol, increasing triglycerides
and glucose level and having a greater weight loss
(0.90 kg in intervention group) at 5-year follow-up, whereas
controls gained +2.35 kg in weight at the same time.
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Pharmacological interventions
Few studies of the most commonly used weight reduction
drugs examined effects on cardiovascular risk factors.
Thereby, several pharmacological approaches are actually
investigated in order to define their potential role in long-
term therapy (Deedwania and Gupta 2006). Five studies
compared dieting combined with orlistat and single dieting
and found similar positive effects on weight reduction as
well as in terms of reduced cardiovascular risk. For
instance, Davidson et al. (1999) found a decrease in total
cholesterol and LDL cholesterol, as well as serum glucose
and insulin being related to the degree of weight change.
Two longer term investigations with a follow-up of 2 years
showed similar lipid changes. An intervention of a low-
calorie diet with orlistat (Rossner et al. 2000) and a therapy
of orlistat with a specific guidance by a physician on a
reduced energy diet and increase in exercise (Hauptman
et al. 2000) resulted in similar LDL reductions. Besides the
positive effects on LDL cholesterol, also fasting blood
glucose decreased in an 18-month orlistat plus diet trial
(Krempf et al. 2003). The 4-year long XENDOS study
investigated the changes in diabetes incidence during a
lifestyle weight-reduction programme plus orlistat or
placebo (Torgerson et al. 2004) and found a significant
reduction of the diabetes incidence in the orlistat group
only. The latest article on orlistat and a very low energy diet
(Richelsen et al. 2007) underlines the earlier results.
Subjects treated with orlistat showed less weight regain
after 3 years of treatment, but no differences in cardiovas-
cular risk factors compared with a very low energy diet.
However, the incidence rate of newly diagnosed type 2
diabetes was lower in the orlistat group.
Additionally, the Diabetes Prevention Program Research
Group (2002) investigated changes of the incidence rate by
using a combination of diet and metformin, an oral
antidiabetic agent, in a non-diabetic patient sample with
impaired glucose tolerance during an average follow-up of
2.8 years. They compared the metformin group with a
placebo group and an intensive lifestyle therapy, in which
participants received a 16-lesson curriculum on diet,
exercise and behaviour modification. Lifestyle changes
and treatment with metformin showed both effects on
weight loss and changed fasting blood glucose levels, but
lifestyle treatment was more effective in reducing the
incidence rate of diabetes. A multicenter study with
acarbose, another antidiabetic drug, achieved a significant
risk reduction in developing a cardiovascular disease (e.g.,
stroke, myocardial infarction, or sudden death) and in
hypertension incidence in the intervention sample of
patients with impaired glucose tolerance (Chiasson et al.
2003). Participants had received encouragement to improve
exercise and to lose weight and take either acarbose or
placebo. To date, no other research group has published
similar results with antidiabetic therapy modalities; however,
other anti-obesity drugs are currently being investigated.
For the newer substances such as sibutramine and
rimonabant, several studies exist showing their positive
effects on weight and metabolism for at least 1 year
(Curioni and Andre 2006). Regarding long-term change of
cardiovascular risk factors only one study investigated
changes of lipid levels and blood pressure during a
treatment with sibutramine at 24 months. All patients
participated in a 6-month diet and exercise therapy (James
et al. 2000). During the 18-month weight maintenance,
those randomly assigned to the intervention group received
10 mg sibutramine and the control group a placebo. All
patients showed a decrease in triglycerides, LDL cholester-
ol and insulin during the first 6 months, but only in the
sibutramine group were changes sustained. HDL cholester-
ol rose positively in both groups during the 2nd year.
Despite the fact that the intervention group reduced more
weight, their blood pressure increased in an unfavourable
way and 3% of the patients had to be withdrawn because of
their hypertonic reaction.
Another anti-obesity drug in the late-stages of clinical
development is rimonabant, a selective endocannabinoid
antagonist. A critical review of the Cochrane collaboration
(Curioni and Andre 2006) described four existing interven-
tion studies: RIO-Europe (Van Gaal et al. 2005), RIO-
Lipids (Despres et al. 2005), RIO-Diabetes (Hollander
2007), and RIO North America Study (Pi-Sunyer et al.
2006). Three of them had a follow-up of 1 year. Pi-Sunyer
et al. (2006) showed significantly more weight loss for 20 mg
rimonabant compared to placebo, lower levels of triglycerides
and a marked increase in high-density lipoprotein levels in the
1st year for the rimonabant-treated group. In the 2nd year,
those switched from rimonabant to placebo had a weight
regain, whereas those who were maintained on rimonabant
had a sustained weight loss combinedwith positive changes in
cardiometabolic risk factors.
Discussion
The aim of the systematic review was to describe the
current evidence of non-surgical obesity treatment on
cardiovascular risk reduction. Considering that obesity is a
chronic disease of multifactorial aetiology (Orzano and
Scott 2004), long-term treatment seems to be necessary for
successful improvement in well-being and general health.
Reviewing the literature, a great variety of approaches, such
as dieting, exercising, behavioural and pharmacological
treatment, was found, most of them comparing diet with
exercising and exercising combined with medication.
Generally, data on the evidence of non-surgical treatment
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of obesity (including very low calorie diets and cognitive
behavioural therapy) revealed that the effect of such
interventions is marked and has been classified as evidence
A (McTigue et al. 2003; Shaw et al. 2007a, b).
The review of RCTs indicates evidence for improved
blood pressure by dieting and by behavioural therapy.
Thereby, lipids improved in a favourable way in diet
interventions, exercising, pharmacotherapy (like orlistat,
sibutramine and rimonabant), and combined therapies.
Obviously, medications such as orlistat, sibutramine, and
rimonabant are able to add supplemental benefits compared
to the therapies where weight loss alone is the aim (such as
low-calorie diets or exercising). However, it remains to be
elucidated whether and to what extent regular physical
exercise exerts an additional effect to weight loss on blood
lipids. Similarly, effects on glucose or insulin levels were
found in diet, exercise, combined treatment, behavioural
therapy, and medication. Furthermore, reductions in the use
of antihypertensive medication and in prevention of
diabetes were detected. For these two cardiovascular risk
factors, newer studies showed an augmented response of
specific medication such as rimonabant and GLP-1 agonists
(Aronne and Thornton-Jones 2007) compared to weight
loss induced by behavioural therapy, low-calorie diet, and
low vs. high carbohydrate diet.
According to these findings evidence exists that non-
surgical weight reduction programmes are associated with
significant and clinically relevant changes in cardiovascular
risk factors, although the effect on cardiovascular risk
might depend on the degree of successful weight loss. The
discussion of the amount of weight loss needed to improve
the risk situation is ongoing, and to date the evidence of a
meaningful impact on health of the amount of the weight
loss achieved leads to recommendations that a small weight
loss of 1% (Reisin et al. 1978) to 2% (Kannel et al. 2002),
to modest weight loss of 10% loss of baseline weight
(Goldstein 1992; Orzano and Scott 2004) in 1 year has
effects on blood pressure, cholesterol level and glycemic
control. Similarly a modest weight loss of 2.3-kg reduction
decreased a risk factor sum by factors −43% inmen and −40%
in women (Wilson et al. 1999), whereas a 4.5-kg weight loss
by diet and exercise was associated with a 30% type 2
diabetes reduction (Wing et al. 1998). Interestingly, the
Cochrane meta-analysis supports the fact that these cardio-
vascular risk changes under exercise treatment are indepen-
dent of significant weight loss. However, generally lifestyle
therapies such as diet and exercise programmes provide less
than 5 kg weight loss after 2 to 4 years (Douketis et al.
2005), whereas pharmacologic therapy usually leads to 5 to
10 kg weight loss after 1 to 2 years.
Most weight loss studies have methodological limita-
tions that restrict the applicability of findings to obese
people assessed in everyday clinical practice. These
limitations include inadequate study duration, a large
proportions of subjects lost to follow-up, a lack of an
appropriate usual care group, and a lack of reporting of
outcomes in high-risk subgroups. Therefore, the possible
benefit of weight loss on morbidity and mortality has to be
calculated from an amelioration of the cardiovascular risk
profile. Published estimations showed that a reduction of
total cholesterol of 5% combined with an elevation of HDL
cholesterol could result in a reduction of mortality of about
10–15% when reducing body weight by about 10%. A
reduction of blood pressure of about 5–10 mmHg adds
again about 10–15% reduction of mortality (Lean 1998). In
the 20–30% of reduction of mortality, the amount of
cardiovascular mortality does not exceed 15%. However,
positive effects after 1 or 2 years of follow-up are evident.
Clustering risk factors associated with obesity (Various
2001) as done in the metabolic syndrome may help to
facilitate the diagnosis and treatment of the cardiovascular
risk profile of these patients and to mainly reduce low-
density lipoprotein (LDL) cholesterol in specific groups of
individuals as an aim of a secondary prevention strategy. In
concert with the ATP III recommendations [Adult Treat-
ment Panel (version 3) of the US National Institutes of
Health; see: Various 2001], the American Heart Association
(AHA) and the American Diabetes Association (ADA)
called for a joint effort to identify and treat cardiovascular
and metabolic risk factors such as impaired glucose
tolerance, prediabetes, arterial hypertension, dyslipidemia
and obesity (Eckel et al. 2006), but no data are available
that show a direct correlation of survival, risk minimization,
or morbidity to the effective amount of weight loss. A slight
but constant weight reduction seems to be equally effective
in cardiovascular risk management as a large weight loss.
Conclusion
This weighted critical review shows that conservative
treatment strategies consisting of pharmacological, behav-
ioural, dietary, exercise and complementary therapies
designed to reduce weight are able to ascertain significant
benefits on cardiovascular risk factors. As the number of
existing RCTs is rather small, more controlled studies in
this area, especially long-term changes (expectedly over
more than 5–10 years) in clinically healthy obese subjects
are needed.
In the future, it should be possible to individually adapt
the most efficient, economic, long-term efficacious therapy
in patients at risk for developing debilitating diseases as a
result of overweight or obesity using conservative and
surgical therapies concurrently. Moreover, the need for
better ways to achieve sustained weight control is as
important as a clear-cut scientific analysis based on RCTs
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in overweight and obesity. Nevertheless, we should
remember that the obesity endemic is not only a medical,
but mainly a societal problem, which on one hand should
be considered in therapy in terms of suitable programmes of
socialization (Scaglione et al. 2004) and on the other hand
in prevention. Thereby, politicians as well as the food
industry should become aware of their role in the
prevention of this debilitating disorder in our population.
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